Thesis
Nebokitug's Phase 3 path in PSC is defined; whether Chemomab can fund it before Q1 2027 runway expires is the central question
Nebokitug, an anti-CCL24 monoclonal antibody, targets primary sclerosing cholangitis, an orphan fibroinflammatory liver disease with no approved therapies. The thesis turns on whether Chemomab can secure financing or a partnership to fund a Phase 3 trial before its Q1 2027 runway expires. The competitive risk is dual: late-stage bile acid modulators like norUDCA and emerging FXR agonists could reach approval first, redefining the PSC standard of care.
Focus
Chemomab securing Phase 3 financing before Q1 2027 cash runway expires
Q3 2026
Bull
The published AJG data, EASL proteomic presentations demonstrating CCL24 target engagement and dose-dependent fibrosis biomarker improvement, and FDA alignment on a single pivotal trial design collectively create a credible scientific package to attract a pharma partner or institutional investors; a partnership, licensing deal, or equity raise at acceptable dilution would fund Phase 3 initiation and substantially re-rate the stock.
Bear
The micro-cap market cap, thin institutional ownership, declining R&D spend signaling capital conservation mode, and absence of approved therapies in PSC making commercial comps difficult could deter large partners; a severely dilutive equity raise or inability to close financing before Q1 2027 would force operational restructuring or dissolution.
Unlock the full thesis for CMMB.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.